Author

J. Quiroz

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Microbiology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 2 Research Focus:host-pathogen & immune response· 2 Organism:human· 1 Assay:proteomics· 1

Frequent Co-Authors

A. Mengotto· 2 shared A. S. Herbert· 2 shared A. S. Wirchnianski· 2 shared C. Florez· 2 shared D. Haslwanter· 2 shared E. Laudermilch· 2 shared G. Lasso· 2 shared J. Barnhill· 2 shared

Activity by Year

2020-2021 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersMicrobiology

A. Mengotto

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

A combination of RBD and NTD neutralizing antibodies limits the generation of SARS-CoV-2 spike neutralization-escape mutants

D. Haslwanter, M. E. Dieterle, A. Z. Wec, C. M. O'Brien, M. Sakharkar, C. Florez, K. Tong, C. G. Rappazzo, G. Lasso, O. Vergnolle, A. S. Wirchnianski, R. H. Bortz, E. Laudermilch, J. M. Fels, A. Mengotto, , R. K. Jangra

This paper identifies NTD-targeting neutralizing antibodies and shows that combining RBD and NTD antibodies reduces the emergence of neutralization-escape mutants.

mBio · Oct 26, 2021Peer-reviewedMicrobiology

A replication-competent vesicular stomatitis virus for studies of SARS-CoV-2 spike-mediated cell entry and its inhibition

M. E. Dieterle, D. Haslwanter, R. H. Bortz, A. S. Wirchnianski, G. Lasso, O. Vergnolle, S. A. Abbasi, J. M. Fels, E. Laudermilch, C. Florez, A. Mengotto, D. Kimmel, R. J. Malonis, G. Georgiev, J. Quiroz, , R. K. Jangra

This paper develops a recombinant vesicular stomatitis virus expressing SARS-CoV-2 spike protein to assess neutralizing antibodies in convalescent sera and validate its utility for vaccine and therapeutic development.

bioRxiv · May 20, 2020Microbiology